US BioDefense forms bioengineered skin deal
This article was originally published in Clinica
Executive Summary
US BioDefense, a Department of Defense central contractor, has signed an option licence agreement with a major university to evaluate an adult stem cell sorting and enrichment technology that could be applied to gene therapy and bioengineered skin technology, which is a $1bn market.